# Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

> **NCT03095638** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 38 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Conventional dolutegravir 10 mg tablet
- **DRUG:** Conventional dolutegravir 50 mg tablet
- **DRUG:** Dispersible dolutegravir 5 mg tablet
- **DRUG:** Conventional dolutegravir 25 mg tablet

## Key facts

- **NCT ID:** NCT03095638
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-03
- **Primary completion:** 2017-06-23
- **Final completion:** 2017-06-23
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03095638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03095638, "Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03095638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*